| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| OPTIMA MEDICAL INNOVATIONS Aktie jetzt für 0€ handeln |
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| AURORA CANNABIS | 2,925 | -0,85 % | Aurora Cannabis Inc.: Aurora Cannabis Announces Fiscal 2026 Third Quarter Results | NASDAQ | TSX: ACB
Expands YoY Total Net Revenue1 by 7% to $94.2 million, with Global Medical Cannabis Net Revenue1 Increasing by 12% to a Record $76.2 million
... ► Artikel lesen | |
| CANOPY GROWTH | 0,935 | -0,95 % | Canopy Growth: Treffer ohne Gewinn - Trading-Tipp wird zurückgezogen | ||
| TILRAY BRANDS | 6,450 | +0,62 % | Tilray Brands, Inc.: CC Pharma von Tilray als eines der 100 innovativsten Unternehmen in Deutschland ausgezeichnet | Die Auszeichnung würdigt CC Pharma als innovativen Marktführer und vertrauenswürdigen Partner auf dem europäischen PharmamarktDENSBORN, Deutschland, Feb. 04, 2026 (GLOBE NEWSWIRE) -- Tilray Pharma,... ► Artikel lesen | |
| ABBOTT LABORATORIES | 93,98 | +0,23 % | Abbott Reports Positive 12-month Results From VOLT-AF IDE Study | NORTH CHICAGO (dpa-AFX) - Abbott (ABT) announced clinical data from two presentations at AF Symposium in Boston that demonstrate the strong safety and efficacy of the company's minimally invasive... ► Artikel lesen | |
| SINOPHARM | 2,366 | +0,55 % | Sinopharm Group-Aktie heute gut behauptet: Aktienwert steigt (2,08 €) | Der Anteilsschein der Sinopharm Group notiert heute ein wenig fester. Zuletzt zahlten Investoren für das Wertpapier 2,08 Euro. Jahreschart der Sinopharm Group Ltd-Aktie, Stand 11.09.2025 Freuen können... ► Artikel lesen | |
| AMARIN | 12,500 | 0,00 % | Amarin Corporation plc: Amarin Applauds Breakthroughs In Therapies For Patients With Elevated Triglycerides; Company's VASCEPA/VAZKEPA (Icosapent Ethyl) Franchise Well Positioned To Benefit Globally From Broadened Category Commercialization | DUBLIN and BRIDGEWATER, N.J., Jan. 09, 2026 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ: AMRN), a company advancing the science of cardiovascular therapeutics worldwide, today commented on... ► Artikel lesen | |
| ACADIA PHARMACEUTICALS | 19,970 | +0,25 % | Acadia Pharmaceuticals Inc.: Acadia Pharmaceuticals Provides Update on Regulatory Submission for Trofinetide for the Treatment of Rett Syndrome in the European Union | - Company expects to receive a negative opinion following oral explanation feedback and intends to request re-examination upon review of formal adoption.
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD)... ► Artikel lesen | |
| BRIDGEBIO PHARMA | 57,98 | +0,73 % | BridgeBio shares slide amid report that Pfizer will withdraw Vyndamax EU patent | ||
| CNBX PHARMACEUTICALS | - | - | CNBX Pharmaceuticals Inc. - 10-Q, Quarterly Report | ||
| AURINIA PHARMACEUTICALS | 12,090 | -0,98 % | Wachstumssorgen: Leerink Partners stuft Aurinia Pharmaceuticals herab | ||
| ARGENT BIOPHARMA | 0,038 | +19,05 % | Argent BioPharma Ltd.: Argent is Growing Through M&A: Projected Merged Company Value of $100M in AC8 Asset Acquisition | Acquisition Expands Clinical Pipeline, Strengthens IP Portfolio, and Grows EU Presence
Highlights
Binding term sheet signed to acquire key assets and IP of AusCann... ► Artikel lesen | |
| CENTR BRANDS | 0,001 | 0,00 % | Centr Brands Corp (2): Centr Brands arranges $50,000 debenture financing | ||
| LABORATORIOS FARMACEUTICOS ROVI | 72,75 | -0,07 % | Rovi continues to show interesting medium-term upside potential, pointing to levels of €96, surpassing all-time highs of €92 | ||
| AVECHO BIOTECHNOLOGY | 0,006 | 0,00 % | AVECHO BIOTECHNOLOGY LIMITED: Avecho CEO to Present at Euroz Hartleys Healthcare Forum | ||
| HERON THERAPEUTICS | 1,065 | 0,00 % | Heron Therapeutics, Inc.: Heron Therapeutics Announces Preliminary, Unaudited Q4 and Full-Year 2025 Net Revenue; ZYNRELEF Largest Contributor to Q4 Growth | CARY, N.C., Jan. 09, 2026 (GLOBE NEWSWIRE) -- Heron Therapeutics, Inc. (Nasdaq: HRTX) ("Heron" or the "Company"), a commercial-stage biotechnology company, today announced preliminary, unaudited fourth... ► Artikel lesen |